LEO Pharma A/S

A decade ago, Almirall took the strategic decision to focus exclusively on medical dermatology, and after posting a strong set of financials for 2024, CEO Carlos Gallardo has told investors that “I’m

Leo Pharma has posted a strong set of financials for 2024, a year which saw the Danish drugmaker nail its three ambitions of increasing top-line growth, improving profitability and advancing in innova

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do